OverviewSuggest Edit

Soleno Therapeutics (formerly Capnia) is a private company developing novel therapeutic products using its proprietary medical gas delivery system. The Company is targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Soleno has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures end-tidal carbon monoxide (ETCO) for the detection of dangerous hemolysis rates. Non-invasive hemolysis detection has important applications for the neonatology market, and newborn care will be an initial commercial focus for the product.

TypePublic
Founded1999
HQRedwood City, CA, US
Websitecapnia.com

Latest Updates

Employees (est.) (Dec 2019)12(+34%)
Revenue (FY, 2016)$1.5 M(+139%)
Share Price (Sept 2021)$0.9(-1%)
Cybersecurity ratingBMore

Key People/Management at Soleno Therapeutics

Tony Wondka

Tony Wondka

Senior Vice President and General Manager

Soleno Therapeutics Office Locations

Soleno Therapeutics has offices in Redwood City and Foster City
Redwood City, CA, US (HQ)
1235 Radio Rd #110
Foster City, CA, US
1101 Chess Dr
Show all (2)

Soleno Therapeutics Financials and Metrics

Soleno Therapeutics Revenue

Soleno Therapeutics's revenue was reported to be $1.45 m in FY, 2016
USD

Net income (Q1, 2021)

(9.0m)

EBIT (Q1, 2021)

(9.2m)

Market capitalization (14-Sept-2021)

70.6m

Closing stock price (14-Sept-2021)

0.9

Cash (31-Mar-2021)

41.6m

EV

29.0m
Soleno Therapeutics's current market capitalization is $70.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

607.5k1.5m

Cost of goods sold

352.7k1.5m

Gross profit

254.8k(58.5k)

Gross profit Margin, %

42%(4%)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

22.0k97.0k247.0k447.0k391.0k329.0k265.0k1.0k

Cost of goods sold

18.0k22.0k461.0k428.0k399.0k209.0k42.0k

Gross profit

4.0k75.0k(14.0k)(37.0k)(70.0k)56.0k(41.0k)

Gross profit Margin, %

18%77%(3%)(9%)(21%)21%(4100%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.0m5.5m2.7m17.1m23.1m20.7m49.2m

Accounts Receivable

156.1k133.3k

Prepaid Expenses

252.3k167.6k342.9k529.0k411.0k1.0m

Inventories

109.3k551.0k660.4k
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

64.0k9.5m7.5m4.7m6.5m2.5m5.4m10.5m7.5m5.6m14.9m12.6m10.2m19.4m15.5m11.2m15.1m62.5m41.6m

Accounts Receivable

37.0k8.0k12.0k94.0k187.0k288.0k137.0k110.0k3.0k

Prepaid Expenses

186.0k260.0k311.0k225.0k216.0k157.0k217.0k261.0k246.0k145.0k423.0k248.0k327.0k603.0k471.0k375.0k572.0k505.0k921.0k

Inventories

206.0k277.0k376.0k653.0k774.0k703.0k855.0k164.0k
Show all financial metrics

Soleno Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Soleno Therapeutics Online and Social Media Presence

Embed Graph

Soleno Therapeutics News and Updates

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a

REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted its…

Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021

European Key Opinion Leaders to Participate in Event European Key Opinion Leaders to Participate in Event

Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit

REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present…

Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall

REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, participat…

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the fourt…
Show more

Soleno Therapeutics Frequently Asked Questions

  • When was Soleno Therapeutics founded?

    Soleno Therapeutics was founded in 1999.

  • Who are Soleno Therapeutics key executives?

    Soleno Therapeutics's key executives are Tony Wondka.

  • How many employees does Soleno Therapeutics have?

    Soleno Therapeutics has 12 employees.

  • Who are Soleno Therapeutics competitors?

    Competitors of Soleno Therapeutics include CIGA Healthcare, Corscience and DEAM.

  • Where is Soleno Therapeutics headquarters?

    Soleno Therapeutics headquarters is located at 1235 Radio Rd #110, Redwood City.

  • Where are Soleno Therapeutics offices?

    Soleno Therapeutics has offices in Redwood City and Foster City.

  • How many offices does Soleno Therapeutics have?

    Soleno Therapeutics has 2 offices.